758 related articles for article (PubMed ID: 27465835)
21. EphA2 Expression in Bone Sarcomas: Bioinformatic Analyses and Preclinical Characterization in Patient-Derived Models of Osteosarcoma, Ewing's Sarcoma and Chondrosarcoma.
Giordano G; Merlini A; Ferrero G; Mesiano G; Fiorino E; Brusco S; Centomo ML; Leuci V; D'Ambrosio L; Aglietta M; Sangiolo D; Grignani G; Pignochino Y
Cells; 2021 Oct; 10(11):. PubMed ID: 34831119
[TBL] [Abstract][Full Text] [Related]
22. Survival of patients with malignant primary osseous spinal neoplasms: results from the Surveillance, Epidemiology, and End Results (SEER) database from 1973 to 2003.
Mukherjee D; Chaichana KL; Gokaslan ZL; Aaronson O; Cheng JS; McGirt MJ
J Neurosurg Spine; 2011 Feb; 14(2):143-50. PubMed ID: 21184634
[TBL] [Abstract][Full Text] [Related]
23. Bayesian pretest probability estimation for primary malignant bone tumors based on the Surveillance, Epidemiology and End Results Program (SEER) database.
Benndorf M; Neubauer J; Langer M; Kotter E
Int J Comput Assist Radiol Surg; 2017 Mar; 12(3):485-491. PubMed ID: 27722873
[TBL] [Abstract][Full Text] [Related]
24. Periosteal osteosarcoma and parosteal chondrosarcoma evaluated by double immunohistochemical staining. Report of 2 cases.
Chano T; Matsumoto K; Ishizawa M; Morimoto S; Hukuda S; Okabe H
Acta Orthop Scand; 1994 Jun; 65(3):355-8. PubMed ID: 7518993
[TBL] [Abstract][Full Text] [Related]
25. Expression of SATB2 in primary cutaneous sarcomatoid neoplasms: a potential diagnostic pitfall.
Szczepanski JM; Siddiqui J; Patel RM; Harms PW; Hrycaj SM; Chan MP
Pathology; 2023 Apr; 55(3):350-354. PubMed ID: 36732203
[TBL] [Abstract][Full Text] [Related]
26. FGF23 Expression Is a Promising Immunohistochemical Diagnostic Marker for Undifferentiated Pleomorphic Sarcoma of Bone (UPSb).
Al-Hassi HO; Ali NM; Cooke H; De Silva S; Brini AT; Babu P; Sumathi V; Morris MR; Niada S
Genes (Basel); 2024 Feb; 15(2):. PubMed ID: 38397231
[No Abstract] [Full Text] [Related]
27. Primary sclerosing epithelioid fibrosarcoma of bone: analysis of a series.
Wojcik JB; Bellizzi AM; Dal Cin P; Bredella MA; Fletcher CD; Hornicek FJ; Deshpande V; Hornick JL; Nielsen GP
Am J Surg Pathol; 2014 Nov; 38(11):1538-44. PubMed ID: 24921641
[TBL] [Abstract][Full Text] [Related]
28. Oncostatin M is a growth factor for Ewing sarcoma.
David E; Tirode F; Baud'huin M; Guihard P; Laud K; Delattre O; Heymann MF; Heymann D; Redini F; Blanchard F
Am J Pathol; 2012 Nov; 181(5):1782-95. PubMed ID: 22982441
[TBL] [Abstract][Full Text] [Related]
29. The ultrastructure of small-cell osteosarcoma, with a review of the light microscopy and differential diagnosis.
Dickersin GR; Rosenberg AE
Hum Pathol; 1991 Mar; 22(3):267-75. PubMed ID: 2004750
[TBL] [Abstract][Full Text] [Related]
30. NKX2.2 is a useful immunohistochemical marker for Ewing sarcoma.
Yoshida A; Sekine S; Tsuta K; Fukayama M; Furuta K; Tsuda H
Am J Surg Pathol; 2012 Jul; 36(7):993-9. PubMed ID: 22446943
[TBL] [Abstract][Full Text] [Related]
31. Histogenesis of clear cell chondrosarcoma. An immunohistochemical study with osteonectin, a non-collagenous structure protein.
Bosse A; Ueda Y; Wuisman P; Jones DB; Vollmer E; Roessner A
J Cancer Res Clin Oncol; 1991; 117(1):43-9. PubMed ID: 1997469
[TBL] [Abstract][Full Text] [Related]
32. [Malignant bone tumors of the hand].
Schnürer S; Horch RE
Handchir Mikrochir Plast Chir; 2013 Jun; 45(3):152-8. PubMed ID: 23860700
[TBL] [Abstract][Full Text] [Related]
33. Experimental therapies and clinical trials in bone sarcoma.
Chugh R
J Natl Compr Canc Netw; 2010 Jun; 8(6):715-25. PubMed ID: 20581301
[TBL] [Abstract][Full Text] [Related]
34. SATB2 and MDM2 Immunoexpression and Diagnostic Role in Primary Osteosarcomas of the Jaw.
Owosho AA; Ladeji AM; Adesina OM; Adebiyi KE; Olajide MA; Okunade T; Palmer J; Kehinde T; Vos JA; Cole G; Summersgill KF
Dent J (Basel); 2021 Dec; 10(1):. PubMed ID: 35049602
[TBL] [Abstract][Full Text] [Related]
35. NKX3.1 a useful marker for mesenchymal chondrosarcoma: An immunohistochemical study.
Syed M; Mushtaq S; Loya A; Hassan U
Ann Diagn Pathol; 2021 Feb; 50():151660. PubMed ID: 33302222
[TBL] [Abstract][Full Text] [Related]
36. Correlation NKX2.2 IHC and
Pasricha S; Pahwa S; Pruthi M; Jajodia A; Gupta G; Sharma A; Durga G; Kamboj M; Tiwari A; Panigrahi M; Mehta A
Indian J Pathol Microbiol; 2023; 66(1):58-62. PubMed ID: 36656211
[TBL] [Abstract][Full Text] [Related]
37. Expression of bone morphogenetic proteins and receptors in sarcomas.
Guo W; Gorlick R; Ladanyi M; Meyers PA; Huvos AG; Bertino JR; Healey JH
Clin Orthop Relat Res; 1999 Aug; (365):175-83. PubMed ID: 10627702
[TBL] [Abstract][Full Text] [Related]
38. [Interdisciplinary diagnostic and treatment of bone sarcomas of the extremities and trunk].
Andreou D; Hardes J; Gosheger G; Henrichs MP; Nottrott M; Streitbürger A
Handchir Mikrochir Plast Chir; 2015 Apr; 47(2):90-9. PubMed ID: 25897578
[TBL] [Abstract][Full Text] [Related]
39. Expression of c-met proto-oncogene product (c-MET) in benign and malignant bone tumors.
Naka T; Iwamoto Y; Shinohara N; Ushijima M; Chuman H; Tsuneyoshi M
Mod Pathol; 1997 Aug; 10(8):832-8. PubMed ID: 9267827
[TBL] [Abstract][Full Text] [Related]
40. Pathology of primary malignant bone and cartilage tumours.
Rozeman LB; Cleton-Jansen AM; Hogendoorn PC
Int Orthop; 2006 Dec; 30(6):437-44. PubMed ID: 16944143
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
